New Report Reveals 340B Program's Impact on Executive Compensation and Charity Care Provision

ADAP Advocacy and the Community Access National Network (CANN) released a report on the 340B Drug Pricing Program, revealing a significant increase in annual revenues and executive compensation for covered entities. The report, titled 'The 340B Drug Pricing Program and its Potential Impacts on Annual Revenues, Executive Compensation, and Charity Care Provision in Eligible Covered Entities,' highlighted the program's financial benefits for hospitals and mega service providers. The CEO of ADAP Advocacy, Brandon M. Macsata, emphasized the need to address the program's skewed priorities and return it to its original intent of helping patients.

The report analyzed IRS 990 filings for 69 340B-eligible covered entities, including HIV care providers and hospitals, to assess revenue, executive compensation, and charity care provision. The findings underscore the financial gains for covered entities and the decline in charity care levels over time. The full report is available for download, and for more information, interested parties can contact ADAP Advocacy.